TABLE 2.

Patterns of Use of First-Line Systemic Therapies for mRCC (N = 649)

Medication	n	Median (Range) Starting Dose, mg	Median (Range) Ending Dose, mg	Days to First-Line Treatment Discontinuation, Days ± SD	n	Days to Switch in Therapy, Mean ± SD
Injectable
Temsirolimus	95	25.0 (12.5-50.0)a	25.0 (12.5-50.0)a	171.8 ± 26.2	6	102.7 ± 37.8
Bevacizumab	28	700.0 (650.0-900.0)b	700.0 (650.0-900.0)b	150.8 ± 56.0	3	20.7 ± 32.3
Oral
Sunitinib	282	33.3 (12.5-50.0)c	25.0 (12.5-50.0)c	169.0 ± 29.5	36	109.2 ± 46.3
Sorafenib	91	800.0 (800.0-800.0)d	800.0 (800.0-800.0)d	160.1 ± 41.4	12	81.8 ± 57.1
Pazopanib	62	800.0 (800.0-800.0)e	800.0 (800.0-800.0)e	160.3 ± 41.1	10	71.9 ± 28.0
Everolimus	32	10.0 (5.0-10.0)f	10.0 (5.0-10.0)f	137.0 ± 62.2	11	63.6 ± 47.4

^aRecommended dose: 25 mg intravenous infusion once weekly.¹⁵

^bRecommended dose: 10 mg/kg intravenous infusion every 2 weeks with interferon alfa.¹⁶

^cRecommended dose: 50 mg once daily, 4 weeks on treatment followed by 2 weeks off.¹⁷

^dRecommended dose: 400 mg twice daily.¹⁸

^eRecommended dose: 800 mg once daily.¹⁹

^fRecommended dose: 10 mg once daily.²⁰

mRCC = metastatic renal cell carcinoma; SD = standard deviation.